Observational analysis reveals elevated ILC2 levels and IL-25 signaling in chronic rhinosinusitis with nasal polyps, indicating potential for new treatments.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by Th2-type inflammation and is associated with dysregulated interleukin-25 (IL-25) expression. Type II innate lymphoid cells (ILC2s), as potential effector cells of IL-25, may contribute to the pathogenesis of CRSwNP. However, their specific role in nasal polyp (NP) tissues, particularly in Chinese patients, remains insufficiently understood. Nasal polyp (NP) tissue and turbinate mucosa (TM) were collected from 37 Chinese CRSwNP patients undergoing surgery. TM samples from 7 patients with pituitary tumors were used as controls. IL-25 expression, Th2 cytokines, phosphorylated STAT3 (p-STAT3), and ILC2 levels were assessed via immunohistochemistry, flow cytometry, and ELISA. Isolated ILC2s from NP tissues were stimulated with IL-25, with or without limonin treatment, to evaluate downstream cytokine production and STAT3 activation. Compared to control TM, both NPs and TM from CRSwNP patients showed elevated IL-25 expression. NP tissues exhibited increased p-STAT3 levels and overexpression of Th2 cytokines. ILC2s were significantly more abundant in NPs and TM of CRSwNP patients. Upon IL-25 stimulation, NP-derived ILC2s produced higher levels of IL-5 and IL-13, accompanied by enhanced STAT3 phosphorylation. Limonin treatment significantly reduced both STAT3 activation and Th2 cytokine production in IL-25-stimulated NP tissues. ILC2s function as key effector cells of IL-25 in CRSwNP, promoting type-2 inflammation via the STAT3 signaling pathway. Limonin attenuates this response and may serve as a promising therapeutic agent for CRSwNP by targeting IL-25/STAT3-driven ILC2 activation.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: